A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach.
| Publicado en: | Oncology & Therapy Vol. 8; no. 1; pp. 91 - 103 |
|---|---|
| Autores principales: | , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jun2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143223948&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143223948 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23661070 JQW4 jtl: Oncology & Therapy issn: 23661070 maglogo: N pubinfo: dt: Jun2020 vid: 8 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 143223948 10.1007/s40487-019-0097-7 143223948 ppf: 91 ppct: 12 formats: tig: atl: A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach. aug: au: Wang, Xiaomin Chen, Jian Reyes, Josephine Zhou, Simon Palmisano, Maria Li, Yan affil: Non-Clinical Development, Celgene Corporation, Summit, NJ, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|